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This systematic review summarizes the evidence regarding the quality of patient-reported outcome
measures (PROMs) validated in patients with obstructive sleep apnea (OSA). We performed a systematic
literature search of all PROMs validated in patients with OSA, and found 22 measures meeting our in-
clusion criteria. The quality of the studies was assessed using the consensus-based standards for the
selection of health status measurement instruments (COSMIN) checklist. The results showed that most of
the measurement properties of the PROMs were not, or not adequately, assessed. For many identiﬁed
PROMs there was no involvement of patients with OSA during their development or before the PROM
was tested in patients with OSA. Positive exceptions and the best current candidates for assessing health
status in patients with OSA are the sleep apnea quality of life index (SAQLI), Maugeri obstructive sleep
apnea syndrome (MOSAS) questionnaire, Quebec sleep questionnaire (QSQ) and the obstructive sleep
apnea patient-oriented severity index (OSAPOSI). Even though there is not enough evidence to fully
judge the quality of these PROMs as outcome measure, when interpreted with caution, they have the
potential to add value to clinical research and clinical practice in evaluating aspects of health status that
are important to patients.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Obstructive sleep apnea (OSA) is characterized by repeated ep-
isodes of complete obstruction of the upper airway, resulting in
oxygen desaturation and arousal from sleep. The prevalence of OSA
is 2e5% in adult women and 3e7% in adult men [1]. The symptoms
that these patients may experience are sleepiness, morning head-
aches, tiredness and fatigue, reduced vigilance and executive
function, memory impairment, depression and impotence. Un-
treated OSA has been shown to be associated with cardiaccal Center, IQ Healthcare, PO
rlands. Tel.: þ31 24 3616359.
bma).
Ltd. This is an open access article upathologies (heart failure, arrhythmias, and ischemic heart disease)
and stroke, as well as diabetes [1e3]. Speciﬁcally related to daytime
sleepiness, the risk of road trafﬁc accidents, near miss events and
falling asleep at the wheel is signiﬁcantly increased in severe OSA
[4]. There is also evidence that untreated patients use more health
services, take more medication, and are more often unemployed
[4,5].
Successful treatment of OSA is often deﬁned as demonstrating a
reduction in the number of obstructive events occurring during
each hour of sleep [6,7]. This is, however, weakly (or not at all)
correlated with quality of life and daytime symptoms as experi-
enced by patients with OSA [8e10]. To determine outcomes of
treatment relevant to the experience of patients, patient-reported
outcomes should be included for measuring the views of patients
on their health and health-related quality of life [6,8,11].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations
BAI Beck anxiety inventory
COSMIN consensus-based standards for the selection of health
status measurement instruments
CPAP continuous positive airway pressure
EQ-5D euroqol-5D
ESS Epworth sleepiness scale
FLP functional limitations proﬁle
FOSQ functional outcomes of sleep questionnaire
HADS hospital anxiety and depression scale
ICC intraclass correlation coefﬁcient
MIC minimal important change
MOSAS Maugeri obstructive sleep apnea syndrome
NHP Nottingham health proﬁle
OSA obstructive sleep apnea
OSAPOSI obstructive sleep apnea patient-oriented severity
index
PGI patient-generated index
PROM patient-reported outcome measure
QSQ Quebec sleep questionnaire
SAQLI sleep apnea quality of life index
SF-12 short-form 12
SF-36 short form 36
SNORE25symptoms of nocturnal obstruction and related
events-25
SOS snore outcomes survey
SQS sleep quality scale
SWIFT sleepiness-wakefulness inability and fatigue test
ToDSS time of day sleepiness scale
VAWS visual analogical well-being scale
Glossary of terms
Patient-reported outcome measure A questionnaire about
health or functioning ﬁlled
out by a patient
Construct That which a questionnaire aims to measure (for
example “sleepiness”)
Reliability The extent to which a measurement is free from
measurement error. For questionnaires this is
assessed with testeretest reliability: the
questionnaire is ﬁlled out twice in a period of time
when no true change has occurred in the construct.
Validity The extent to which an instrument measures the
construct that it aims to measure. Important aspects of
validity are content validity (do the questions
adequately cover the construct, as determined by the
target population of the questionnaire) and construct
validity (the degree towhich scores are consistent with
hypotheses about their correlationwith scores of other
instruments).
Responsiveness The ability of an instrument to detect change
over time in the construct to be measured.
Interpretability The degree to which it is clear what the scores
or change scores of an instrument mean.
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outcome measures (PROMs); questionnaires consisting of one or
more multi-item scales, or single-item measures. These can be
disease-speciﬁc, or generic. Disease-speciﬁc PROMs focus on the
symptoms and/or impact on functioning related to a speciﬁc dis-
ease [12]. Generic PROMs aim to measure important general (as-
pects of) health-related quality of life or general functioning, such
as mobility, or the degree towhich the presence of health problems
affects social functioning.
Initially, PROMs were developed for use in research, but in
recent years their use has expanded to other areas, closer to clinical
practice. That is, they can be used to assess the patient's health
status prior to treatment and to support clinical decision-making.
They may also be used after treatment to evaluate individual pa-
tient beneﬁt by comparison with pre-treatment scores. When
PROMs are operationalized as performance measures, they can be
used to assess whether treatments by healthcare providers (and
organizations) improve the health of patients [12,13].
For a valid and patient-centered evaluation of health status it is
important that PROMs measure aspects of health status that are
important to patients with OSA, and that their measurement
characteristics are adequate for the speciﬁc patient population.
Several literature reviews have assessed the measurement prop-
erties of different PROMs used in patients with OSA [14e18].
However, none of them provided an overview of the quality of all
PROMs for outcome measurement in the speciﬁc target group of
patients with OSA.
In this systematic review we therefore provide an overview of
the quality of PROMs for health outcomes measurement which are
validated in patients with OSA. This provides an evidence base for
the choice of a PROM in clinical practice, for quality assessment, and
in clinical research trials.Methods
Identiﬁcation of PROMs and validation studies
Literature search
A systematic search of the electronic databases MEDLINE,
EMBASE and CINAHL from inception up to November 4th 2014 was
conducted to identify all validation studies of PROMs assessed in
patients with (suspected) OSA. Search terms used were “obstruc-
tive sleep apnea”, “patient-reported outcome measure” and
commonly used synonyms, acronyms, and related terms (Table S1).
Additionally, we used the search ﬁlter for studies describing mea-
surement properties developed by Terwee et al. [19] for our
PubMed search, which has a sensitivity of 97.4%. For the other da-
tabases we developed a comparable ﬁlter with a similar approach
to the PubMed version.
For each PROM identiﬁed in these studies we conducted an
additional search to identify validation studies that our original
searchmay havemissed.We also performed a reference and related
article search. Duplicate articles were manually ﬁltered using the
bibliographic EndNote database, version X5 (Thomas Reuters, New
York City, NY, USA).
Selection of studies
Inclusion criteria for PROMs and validation studies
We included PROMs that have one or more eligible validation
studies in adult patients with OSA and have outcomemeasurement
as (one of) their aims. This means they are potentially suitable for
use in evaluative situations. Furthermore, the PROMs needed to
have been named, allowing identiﬁcation. The aim of the PROM
should be to capture general aspects of health status (such as
I.L. Abma et al. / Sleep Medicine Reviews 28 (2016) 18e3120functional status, general health-related quality of life), OSA-
related quality of life, or symptoms associated speciﬁcally with
OSA, including sleepiness and fatigue, snoring and restless sleep,
and anxiety and depression [20].
Validation studies were included if they studied the PROM in its
original language of development, and if they were published as
original and full text studies in English or Dutch. Furthermore, the
ﬁndings needed to be presented for patients with OSA separately
from any other study population, such as patients with other dis-
orders causing sleepiness.
Two reviewers (IA and VV) independently assessed the eligi-
bility of the identiﬁed PROMs and papers. Any disagreements were
resolved by discussion with a third reviewer (PvdW). Where
necessary we contacted study authors for clariﬁcation and addi-
tional information to inform study selection.
Measurement properties
We used the taxonomy of measurement properties as con-
structed by the COSMIN panel [21]. There are three domains of
measurement properties: reliability, validity and responsiveness.
We assessed all aspects of these domains, except cross-cultural
validity, as we did not include translated PROMs. Additionally, we
assessed interpretability, which is not a measurement property in
itself but is an important characteristic of a measurement
instrument.
Reliability
The reliability of a measurement instrument expresses to which
extent scores are free from measurement error. It consists of three
measurement properties:
 Internal consistency: measures to what extent items in a one-
dimensional (sub)scale are related. It is commonly reported
with the parameter Cronbach's a, which expresses the correla-
tion between the items in the (sub)scale. A separate factor
analysis (see construct validity) is needed to assess the dimen-
sionality of a scale before Cronbach's a can be interpreted [22].
 Reliability: expresses the variance in the measurements which is
due to true differences among patients, i.e., the score without
measurement error. For PROMs this is usually assessed by
testeretest reliability: the extent to which patients who have
had no change in the construct have the same score at repeated
measurements. This can be reported with the intraclass corre-
lation coefﬁcient (ICC) or weighted Kappa.
 Measurement error: All error (systematic and random) in a
measurement that is not due to true differences in the construct
that is measured. Whether the measurement error is acceptable
is determined by comparing the minimally important change
with the smallest detectable change or the limits of agreement.Validity
Validity is the extent to which a measurement instrument
measures what it purports to measure. In this domain three mea-
surement properties can be distinguished:
 Content validity: the extent to which the content of the instru-
ment adequately reﬂects the construct to be measured in a
certain population. This involves a judgment by the target
population itself on the relevance and comprehensiveness of the
items of a PROM.
 Construct validity: the extent to which an instrument validly
measures the construct it purports to measure. This includes: Structural validity, which is the extent to which instrument
scores are an adequate reﬂection of the dimensionality of the
construct, as assessed by factor analysis.
 Hypothesis testing: the degree to which a measurement in-
strument produces outcomes consistent with hypotheses.
These hypotheses state expected outcomes when assuming
that the instrument validlymeasures its construct. Hypothesis
testing can be used to assess convergent validity (the degree
to which scores on instruments with related constructs
correlate), known-groups validity (the ability of an instrument
to distinguish between groups that are expected to differ with
respect to the construct to be measured) and discriminant
validity (assessing whether instruments with unrelated con-
structs have low correlations).
 Criterion validity: the extent to which a measurement instru-
ment is an adequate reﬂection of a gold standard. For PROMs,
a gold standard only exists when a shorter version of a PROM
is created from a longer version, in which case the gold
standard is the longer version of the PROM [23].Responsiveness
Responsiveness is the ability of an instrument to detect change
over time in the construct to be measured. To assess responsive-
ness, hypotheses should be constructed about the change scores of
the instrument under study in correlation to the change scores of
other instruments, as in hypothesis testing for construct validity
[23].
Interpretability
Interpretability assesses to what extent qualitative meaning can
be given to a score or change score of an instrument. Issues that can
be considered in the context of interpretability are ﬂoor and ceiling
effects (<15% of the respondents achieved the highest or lowest
possible scores), scores and change scores in different (sub)groups,
and the minimal important change (MIC) which expresses when a
change score is clinically relevant.
Data extraction
We reviewed the included studies in duplicate (IA and PvdW)
and extracted all reported aspects of reliability, validity and
responsiveness, as well as interpretability of the PROMs.
Assessing the quality of the studies
We used the consensus-based standards for the selection of
health status measurement instruments (COSMIN) checklist [24] to
assess the methodological quality of the included studies. This
checklist contains multiple questions to critically appraise the
methods for each reported measurement property, and uses a four-
point scale [16] (“poor”, “fair”, “good” and “excellent”). The lowest
score counts as the overall score for that property. The quality
assessment was performed by two independent reviewers (IA and
PvdW). Any disagreements were resolved by discussion with a
third reviewer (MR).
Assessing the quality of the PROMs
The reported results of the measurement properties of the
PROMs were judged by criteria based on Terwee et al., 2007 [25]
(Table 1).
For construct validity as well as responsiveness, the quality
criteria call for a comparison of the ﬁndings with hypotheses
constructed by the authors of the papers assessing these
Table 1
Quality criteria for measurement properties [25].
Property Rating Quality criteria
Reliability
Internal consistency þ (Sub)scale unidimensional AND Cronbach's a(s)  0.70
? Dimensionality not known OR Cronbach's a not determined
e (Sub)scale not unidimensional or Cronbach's a(s) < 0.70
Measurement error þ MIC > SDC OR MIC outside the LOA
? MIC not deﬁned
e MIC  SDC OR MIC equals or inside LOA
Reliability þ ICC/weighted Kappa 0.70
? ICC/weighted Kappa not determined
e ICC/weighted Kappa <0.70
Validity
Content validity þ The target population considers all items in the questionnaire to be relevant
? No target population involvement
e The target population considers items in the questionnaire to be irrelevant
OR considers the questionnaire to be incomplete
Construct validity
Structural validity þ Factors should explain at least 50% of the variance
? Explained variance not mentioned
e Factors explain <50% of the variance
Hypothesis testing þ (Correlation with an instrument measuring the same construct  0.50
OR at least 75% of the results are in accordance with hypotheses)
AND correlation with related constructs is higher than with unrelated constructs
? Solely correlations determined with unrelated constructs
e Correlation with an instrument measuring the same construct < 0.50 OR < 75%
of the results are in accordance with the hypotheses OR correlation with related
constructs is lower than with unrelated constructs
Criterion validity þ Convincing arguments that gold standard is ‘‘gold’’ AND correlation
with gold standard > 0.70
? No convincing arguments that gold standard is ‘‘gold’’
e Correlation with gold standard < 0.70, despite adequate design and method
Responsiveness
Responsiveness þ (Correlation with an instrument measuring the same construct  0.50 OR at least 75%
of the results are in accordance with hypotheses OR AUC  0.70) AND correlation with
related constructs is higher than with unrelated constructs
? Solely correlations determined with unrelated constructs
e Correlation with an instrument measuring the same construct < 0.50 OR < 75%
of the results are in accordance with the hypotheses OR AUC < 0.70 OR correlation
with related constructs is lower than with unrelated constructs
AUC e area under the curve; ICC e intraclass correlation coefﬁcient; LOA e limits of agreement; MIC e minimal important change; SDC e smallest detectable change.
þ: positive rating, ?: indeterminate rating, : negative rating.
I.L. Abma et al. / Sleep Medicine Reviews 28 (2016) 18e31 21measurement qualities. However, such hypotheses appear to be
scarce. We therefore decided to follow the strategy of a recent
systematic review [16], in which the authors devised their own
hypotheses where needed. We only devised hypotheses for the
comparator instruments that we thought were suitable for adding
valuable information to the evidence. We considered comparator
instruments unsuitable if the expected relation with the construct
of interest was unclear, or if the comparator instrument had a
(very) different construct than the one under study. A detailed
overview of the hypotheses can be found in Tables S2 and S3.Table 2
Levels of evidence for the overall quality of a measurement property [26].
Level Rating Criteria
Strong þþþ or  Consistent ﬁndings in multi
Moderate þþ or  Consistent ﬁndings in multi
Limited þ or  One study of fair methodolo
quality of reportinga
Conﬂicting ± Conﬂicting ﬁndings
Unknown ? Only studies with a COSMIN
COSMIN e consensus-based standards for the selection of health measurement instrum
þ: positive result, : negative result.
a The COSMIN scores of item 7 and 8 of hypothesis testing and of items 11 and 12 of resp
instruments, assess in their “poor” scores only the quality of the reporting of background
the purpose of determining the level of evidence.Data synthesis
The level of evidence, based on the number and the quality of
the studies, as well as the consistency of the ﬁndings, was sum-
marized for each measurement property based on the method of
Schellingerhout et al. [26] (Table 2). The outcomes table provides
positive, negative or indeterminate evidence scores based on the
quality criteria for the measurement properties and the level of
evidence. The COSMIN scores concerning the descriptions of
(measurement properties of) comparator instruments, which areple studies of good methodological quality OR in one study of excellent quality
ple studies of fair quality OR in one study of good methodological quality
gical quality, or one or more studies with COSMIN score “poor” only due to poor
score of “poor” due to doubtful design or methoda
ents.
onsiveness, concerning the descriptions of (measurement properties of) comparator
information. Therefore we approach “poor” scores on these items as “fair” scores for
I.L. Abma et al. / Sleep Medicine Reviews 28 (2016) 18e3122addressed in “hypothesis testing” and “responsiveness”, assess the
quality of the reporting of background information rather than the
methodological quality of the study. When determining the level of
evidence for these measurement properties, we therefore did not
take “poor” scores for these descriptive items into account. Instead
they were approached as “fair” scores.
There are no quality criteria for interpretability in the COSMIN
checklist, which means the level of evidence cannot be determined
with the method described above. The data on interpretability are
presented in the text.
Statistical pooling was performed for all measurement proper-
ties which were assessed by more than one study with at least a
COSMIN score of “fair”, or a score of “poor” due to a small sample
size. For hypothesis testing and responsiveness the “poor” scores
due to background information only were also included for pooling.
Additionally, for hypothesis testing and responsiveness, we only
pooled correlations between instruments measuring constructs
that we considered suitable (Tables S2 and S3). In cases of high
heterogeneity (>50%), we used a random effects model; for low
heterogeneity (<50%) we used a ﬁxed effects model [27]. A random
effects model is not feasible if only two studies can be pooled. In
cases of high heterogeneity and only two available studies, pooling
was not performed.Results
Selection of studies and PROMs
We identiﬁed 80 eligible validation studies in our primary
search, which all assessed one or more measurement properties of
a total of 39 PROMs (Fig. 1). Additional searches and the reference
check resulted in six new validation studies.
After full-text screening of all the validation studies, 44 studies
and 17 PROMs were excluded because they did not meet ourFig. 1. Flow chart for identiﬁcation of relevant PROMs and validation studies. Oinclusion criteria. This left a total of 42 included studies, assessing
22 PROMs (Table 3). PROMs were divided into three categories:
OSA-related quality of life, single OSA-related symptoms, and
generic health-related quality of life.
We identiﬁed eight OSA-related quality of life PROMs, which
were assessed in 11 studies [28e37]. For all the PROMs in this
category we identiﬁed and included the original development
study, except for the symptoms of nocturnal obstruction and
related events-25 (SNORE25).
We identiﬁed eight PROMs on single OSA-related symptoms
which were (partly) validated for patients with OSA assessed in 27
studies [30,38e63] and six PROMs on generic health-related
quality of life in nine studies [30,47,55,57,64e68]. The former
group includes PROMs which aim to measure sleep propensity/fa-
tigue, snoring, anxiety, and depression.Quality of the included studies
The results of the quality assessment of the studies with the
COSMIN checklist are presented in Table 4. The most common
scores were “poor” and “fair”. For four of the measurement prop-
erties, most studies scored “poor”: internal consistency (10 out of
16 studies), content validity (7 out of 11 studies), criterion validity
(3 out of 3 studies) and responsiveness (19 out of 26 studies). For
structural validity, convergent validity, known-groups validity and
discriminant validity, “fair” was the most common score. Only
content validity and structural validity had one or more “excellent”
scores.
The studies with poor methodological quality for internal con-
sistency did not provide information on the factor structure of the
PROM before calculating Cronbach's a, or calculated Cronbach's a
for the whole PROM rather than separately for each subscale. For
content validity, the “poor” scores were assigned because of a lack
of patient involvement in the design of the PROM or a lackingSA e obstructive sleep apnea; PROM e patient-reported outcome measure.
Table 3
Characteristics of the included PROMs.
Name of instrument Year Language Domain(s) Nr. of questions Original target population Target population involved
in development?
OSA-related quality of life PROMs
Functional outcomes of
sleep questionnaire
(FOSQ) [29]
1997 English Activity level
Vigilance
Intimate and sexual
relationships
General productivity
Social outcome
30 Patients with disorders of
excessive sleepiness
no
Functional outcomes of
sleep questionnaire-10
(FOSQ-10 e shorter
version of the FOSQ) [36]
2009 English Activity level
Vigilance
Intimate and sexual
relationships
General productivity
Social outcome
10 Patients with disorders of
excessive sleepiness
no
Maugeri obstructive sleep
apnea syndrome
(MOSAS) questionnaire
[37]
2011 Italian Sleep apnea psychological
impact
Sleep apnea physical
Impact
Discomfort and nuisance
caused by CPAP
16 (OSA symptoms)
þ7 (CPAP discomfort)
Patients with OSA yes
Obstructive sleep apnea
patient-oriented severity
index (OSAPOSI) [31]
1998 English Sleep problems
Awake problems
Medical problems
Emotional and personal
problems
Occupational impact
32 Patients with OSA yes
Quebec sleep questionnaire
(QSQ) [32]
2004 French Sleepiness
Diurnal symptoms
Nocturnal symptoms
Emotions
Social interactions
32 Patients with OSA yes
Sleep apnea quality of life
indexa (SAQLI) [34]
1998 English Daily functioning
Social interactions
Emotional functioning
Symptoms
þ Treatment related
symptoms
56 þ 28 treatment-related
symptomsb
Patients with sleep-
disordered breathing
yes
Symptoms of nocturnal
obstruction and related
events-25 (SNORE25 -
shorter version of the
OSAPOSI)
?c English Unclear 25 Patients with OSA Yes (patients involved in
development of OSAPOSI)
Visual analogical well-
being scale (VAWS) [33]
2004 Spanish Well-being status with
regard to the symptoms
which were the motive of
the consultation
1 Patients with OSA no
PROMs on single OSA-related symptoms
Beck anxiety inventory
(BAI) [71]
1988 English Anxiety 21 Psychiatric outpatients no
Epworth sleepiness scale
(ESS) [43]
1991 English Sleep propensity 8 Patients with sleep
disorders
no
Hospital anxiety and
depression scale (HADS)
[72]
1983 English Anxiety
Depression
14 Non-psychiatric hospital
patients
no
Rotterdam sleepiness scale
[62]
1995 Dutch Sleepiness 16 Patients with OSA no
Sleepiness-wakefulness
inability and fatigue test
(SWIFT) [61]
2012 English General wakefulness
inability & fatigue (GWIF)
Driving wakefulness
inability & fatigue (DWIF)
12 Patients with OSA no
Sleep quality scale (SQS)
[63]
2006 Korean Restoration after sleep
Difﬁculty in falling asleep
Difﬁculty in getting up
Satisfaction with sleep
Difﬁculty in maintaining
sleep
28 General population Yes (patients with various
sleep disorders involved)
Snore outcomes survey
(SOS) [59]
2002 English (Problems related to)
snoring
8 Patients with complaints of
snoring and sleep-
disordered breathing
no
Time of day sleepiness scale
(ToDSS) [58]
2009 English Sleep propensity at
different times of the day
(questions of ESS repeated
for morning/afternoon/
evening)
24 Patients with OSA,
suspected OSA, or other
primary sleep complaints
no
(continued on next page)
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Table 3 (continued )
Name of instrument Year Language Domain(s) Nr. of questions Original target population Target population involved
in development?
Generic quality of life PROMs
Euroqol (EQ-5D) including
Euroqol thermometer
(EQ-T) [73]
1990 English Mobility
Self-care
Usual activities
Pain/discomfort
Anxiety/depression þ
Global indication of health
status
5 þ 1 General population no
Functional limitations
proﬁle (FLP) [74] (a
British version of the
(American) sickness
impact proﬁle (SIP) [75])
1976 (SIP)
1981 (FLP)
English Ambulation, body care and
movement
Mobility
Household management
Recreation and pastimes
Social interaction
Emotional behavior
Alertness behavior
Sleep and rest
Eating
Communication
Work
136 General population yes (for SIP)
Nottingham health proﬁle
(NHP) part II [76]
1985 English Paid employment
Jobs around the house
Social life
Personal relationships
Sex life
Hobbies and interests
Holidays
7 General population yes
Patient-generated index
(PGI) [77]
1994 English Five most important areas/
activities in the patient's life
affected by their condition
(determined by the
individual patient)
19 Patients with low back pain yes
Short form 12 (SF-12) [78] 1996 English Physical functioning
Role limitations because of
physical health problems
Bodily pain
Social functioning
General mental health
Role limitations because of
emotional problems
Vitality (energy/fatigue)
General health perceptions
12 General population no
Short form 36 (SF-36) [79] 1992 English Physical functioning
Role limitations because of
physical health problems
Bodily pain
Social functioning
General mental health
Role limitations because of
emotional problems
Vitality (energy/fatigue)
General health perceptions
36 General population no
a The SAQLI is interviewer-administered.
b In the “symptoms” domain of the SAQLI, patients indicate for 21 symptoms whether they apply to them or not, with the option of adding symptoms which are not
mentioned. Only the ﬁve most important symptoms are used for scoring. The same method is applied for the 28 treatment-related symptoms.
c No development article could be identiﬁed for the SNORE25.
I.L. Abma et al. / Sleep Medicine Reviews 28 (2016) 18e3124description of the development of the PROM in its development
article. For responsiveness, the most common methodological ﬂaw
was that none of the presented data was suitable for determining
the validity of the change score, for example, when the results of
comparator instruments were not presented in such a way that
they could be related to the instrument under study. One of the
studies on convergent validity scored “poor” solely because of a
missing description of (measurement properties of) the comparator
instrument. For criterion validity, all studies scored “poor” because
they used the data of their criterion to calculate the scores of the
short version of the PROM that was under study, rather than col-
lecting the data for the latter separately. All other studies that
scored “poor” for any of the measurement properties either had astudy population of less than 30 patients, or suffered from a variety
of other methodological ﬂaws.
Measurement properties of the PROMs
The results for the measurement properties of the included
PROMs in the light of their level of evidence can be found in Table 5.
None of the studies in this review assessed measurement error, and
therefore this property was removed from the results table. The
results for all studied measurement properties with a score of “fair”
or better are described below in more detail. The only data meeting
our criteria for pooling were for convergent validity, the results of
which are presented in Table S4.
Table 4
Methodological quality of each study per measurement property and questionnaire.a
Study Internal
consistency
Reliability
(testeretest)
Content
validity
Structural
validity
Hypothesis testing (construct validity) Criterion
validity
Responsiveness
Convergent
validity
Known-groups
validity
Discriminant
validity
OSA-related quality of life PROMs
FOSQ
Billings et al., 2014 [28] Poor Fair, poorb,c Fair
Weaver et al., 1997 [29] Faird Poor Faird Fair, poore,f Poor
Weaver et al., 2005 [30] Fair Poor
FOSQ-10
Chasens et al., 2009 [36] Poor Poor Fair Poor Poor
MOSAS questionnaire
Moroni et al., 2011 [37] Fair Excellent Fair Fair Poor
OSAPOSI
Piccirillo et al., 1998 [31] Poor Excellent Poor Poor
QSQ
Lacasse et al., 2004 [32] Poor Poor Excellent Fair Poor
SAQLI
Billings et al., 2014 [28] Poor Fair, poorb,c Fair
Flemons et al., 1998 [34] Poor Excellent Poor Poor
Flemons et al., 2002 [35] Faird Fair, poorc,g Fair, poorc,g
SNORE25
Weaver et al., 2005 [30] Fair Poor
VAWS
Masa et al., 2011 [33] Good Poor Fair, poorc Poor Fair
PROMs on single OSA-related symptoms
BAI
Sanford et al., 2008 [52] Faird Faird Poorc Fair
ESS
Chervin et al., 1999 [38] Fair, poorc,h Poor
Cowan et al., 2014 [39] Fair
Giudici et al., 2000 [40] Fair
Hardinge et al., 1995 [41] Poor
Hesselbacher et al., 2012 [42] Fair Fair
Johns, 1991 [43] Poor Fair Fair, poori
Johns, 1992 [44] Poor
Johns, 1993 [45] Fair Fair
Johns, 1994 [46] Faird Fair
Kingshott et al., 1995c [48] Fair
Kingshott et al., 1998 [47] Fair
Olaite et al., 2013 [49] Excellent
Olson et al., 1998 [50] Fair
Osman et al., 1999 [51] Fair
Sangal et al., 1999 [53] Fair
Sil et al., 2012 [54] Fair
Smith et al., 2008 [69] Faird Faird
Walter et al., 2002 [56] Fair
Weaver et al., 2004 [57] Fair Poor
Weaver et al., 2005 [30] Fair Poor
HADS
Law et al., 2014 [60] Poor Fair
Kingshott et al., 1998 [47] Fair
Rotterdam sleepiness scale
Van Knippenberg et al., 1995 [62] Poor Fair
SQS
Yi et al., 2009 [63] Poor Fair Fair
SWIFT
Sangal, 2012 [61] Fair Fair Poor
SOS
Gliklich et al., 2002 [59] Poor Poor Poor Fair Poor
ToDSS
Dolan et al., 2009 [58] Faird Poor Faird Poor Poor Poor
Generic health-related quality of life PROMs
EQ-5D
Jenkinson et al., 1997 [67] Poor
Jenkinson et al., 1998 [68] Fair
FLP
Jenkinson et al., 1997 [67] Poor
NHP part II
Kingshott et al., 1998 [47] Fair
PGI
Jenkinson et al., 1998 [68] Fair
SF-12
Jenkinson et al., 1997 [66] Poor Poor
Jenkinson et al., 1997 [65] Poor
(continued on next page)
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Table 4 (continued )
Study Internal
consistency
Reliability
(testeretest)
Content
validity
Structural
validity
Hypothesis testing (construct validity) Criterion
validity
Responsiveness
Convergent
validity
Known-groups
validity
Discriminant
validity
SF-36
Bennett et al., 1999 [64] Fair Poor
Jenkinson et al., 1997 [67] Poor
Jenkinson et al., 1998 [68] Fair
Kingshott et al., 1998 [47] Fair
Smith et al., 1995 [55] Poor Fair,poorj Poor
Weaver et al., 2004 [57] Fair Poor
Weaver et al., 2005 [30] Fair Poor
BAI e Beck anxiety inventory; EQ-5D e euroqol-5D; ESS e Epworth sleepiness scale; FLP e functional limitations proﬁle; FOSQ e functional outcomes of sleep questionnaire;
HADS e hospital anxiety and depression scale; MOSAS e Maugeri obstructive sleep apnea syndrome; NHP e nottingham health proﬁle; OSA e obstructive sleep apnea;
OSAPOSI e obstructive sleep apnea patient-oriented severity index; PGI e patient-generated index; PROM e patient-reported outcome measure; QSQ e Quebec sleep
questionnaire; SAQLIe sleep apnea quality of life index; SF-12e short form 12; SF-36 e short form 36; SNORE25e symptoms of nocturnal obstruction and related events-25;
SOS e snore outcomes survey; SQS e sleep quality scale; SWIFT e sleepiness-wakefulness inability and fatigue test; ToDSS e time of day sleepiness scale; VAWS e visual
analogical well-being scale.
a The measurement property “measurement error” was removed from this table because it was not assessed for any of the instruments.
b “Fair” for comparison with the ESS, “poor” for comparison with the SF-36.
c “Poor” score because of missing description of the questionnaire or its measurement properties.
d Rated “fair” because the percentage of missing items was not described e all other items were good or excellent.
e Rated “fair” due to missing items and/or description of measurement properties of comparator instrument e all other items were good or excellent.
f Hypothesis testing was performed in two groups of different sizes, one of which scored “poor”.
g “Poor” for the comparison instrument “global quality of life rating”, “fair” for the other comparison instruments.
h “Poor” for comparison with a question about problematic sleepiness, “fair” for comparison with the multiple sleep latency test.
i “Poor” for comparing snoring to the different severities of OSA, “fair” for known-groups validity comparing OSA patients and normal subjects.
j “Poor” for comparison of general population with patients with mild OSA, “fair” for comparison of general population with “OSA patients requiring treatment”.
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None of the OSA-related quality of life PROMs was fully vali-
dated. Content validity, convergent validity, internal consistency
and responsiveness were assessed for most of these PROMs,
whereas data on most other measurement properties is not avail-
able. The evidence that is available is often either indeterminate or
of limited strength, due to low study quality. However, most of the
PROMs in this category were developed speciﬁcally for OSA pa-
tients, and four out of eight PROMs have strong positive evidence
for their content validity.
There is strong positive evidence of content validity for the
Maugeri obstructive sleep apnea syndrome (MOSAS) questionnaire,
the obstructive sleep apnea patient-oriented severity index (OSA-
POSI), the Quebec sleep questionnaire (QSQ), and the sleep apnea
quality of life index (SAQLI).
For the functional outcomes of sleep questionnaire (FOSQ) there
is limited positive evidence of structural validity and internal
consistency (Cronbach's a ¼ 0.86e0.91 for the ﬁve factors [29]). For
the MOSAS questionnaire, there is limited negative evidence for
these properties (factors explained 31% of the variance [37]).
Limited andmoderate positive evidence of testeretest reliability
is available for the SAQLI and the visual analogical well-being scale
(VAWS), respectively; the ICC of the SAQLI being 0.92 [35] and that
of the VAWS being 0.83 [33].
For the MOSAS questionnaire, SAQLI and VAWS there is limited
positive evidence for convergent validity. For the FOSQ, evidence on
convergent validity is conﬂicting.Weaver et al. [29] showedweaker
than expected correlations with the short-form 36 (SF-36), while
the correlations found in Billings et al. [28] matched our hypothe-
ses. Due to high statistical heterogeneity, as well as the observation
that all correlations were stronger in Billings et al. [28] than in
Weaver et al. [29], we did not pool the correlations for ﬁve out of
seven comparisons (Table S4). However, we could not identify a
possible explanation for why there was a consistent discrepancy in
these studies.
For the QSQ, less than 75% of the hypotheses for convergent
validity were met. Many correlations did not meet the expectations
stated in its validation article [32]. Therefore, there is limited
negative evidence for convergent validity for this PROM.There is limited positive evidence for known-groups validity of
the FOSQ-10, as patients with OSA had a lower average score than
normal subjects, as was expected.
For the FOSQ, SAQLI and VAWS there is limited positive evidence
for responsiveness.
With regard to interpretability, for the SAQLI and VAWS no
obvious ﬂoor or ceiling effects are reported [33e35]. However, for
the QSQ, the distribution of scores indicates there might be ﬂoor
and ceiling effects in several of its domains [32]. For the FOSQ, QSQ,
and SAQLI, MICs are reported for the separate domains of the
PROMs [28,32,35]. For the FOSQ and FOSQ-10, scores are presented
for patients with OSA and normal subjects [29,36], for the VAWS of
patients before and after treatment with continuous positive
airway pressure (CPAP) [33], and for the MOSAS questionnaire for
patients differing in CPAP adherence [37]. For the other PROMs,
ﬂoor and ceiling effects, MIC, and subgroup scores were not
reported.
PROMs on single OSA-related symptoms
None of the PROMs on single OSA-related symptoms was fully
validated, but the Beck anxiety inventory (BAI) has the most evi-
dence in its favor. Internal consistency and convergent validity
were assessed for most of the PROMs in this category. However, for
three PROMs convergent validity does not seem to be adequate, and
for another three the evidence is indeterminate. Data onmost other
measurement properties is not available for these PROMs. The ev-
idence that is available is often either indeterminate or of limited
strength, due to low study quality.
For the Beck anxiety inventory (BAI) there is a limited positive
level of evidence for structural validity and for internal consistency
(one factor, Cronbach's a ¼ 0.92 [52]). For the ToDSS there is a
limited negative level of evidence for structural validity and inter-
nal consistency, as the variance explained by the factors was below
the required 50% for two of the three subscales [58]. There are
conﬂicting ﬁndings about the factor structure of the Epworth
sleepiness scale (ESS). Johns [46] found a one-factor structure,
Smith et al. [69] reported that two items on low somniﬁcity should
be omitted for a sufﬁcient one-factor ﬁt, and Olaithe et al. [49]
showed a sufﬁcient one-factor ﬁt as well as sufﬁcient three-factor
Table 5
Quality of measurement properties per PROM.a,b
Instrument/patient group Internal
consistency
Reliability
(testeretest)
Content
validity
Structural
validity
Hypothesis testing (construct validity) Criterion
validity
Responsiveness
Convergent
validity
Known-groups
validity
Discriminant
validity
OSA-related quality of life PROMs
FOSQ þ na ? þ ± ? na c þ
FOSQ-10 ? na na na na þ na ? ?
MOSAS questionnaire e na þþþ e þ ? na c na
OSAPOSI ? na þþþ na ? na na c ?
QSQ ? ? þþþ na e na na c ?
SAQLI ? þ þþþ na þ na na c þ
SNORE25 na na na na ? na na c ?
VAWS d þþ ? d þ ? na c þ
PROMs on single OSA-related symptoms
BAI þ na na þ þ na þ c na
ESS ±e na ? ± þ ± na c na
HADS ? na na na e na na c na
Rotterdam sleepiness scale na na ? na e na na c na
SQS ? na na na ? þ na c na
SWIFT na na na na ? þ na c ?
SOS ? ? ? na e na na c ?
ToDSS e na ? e ? ? na c ?
Generic health-related quality of life PROMs
EQ-5D na na na na na na na b e
FLP na na na na na na na b ?
NHP part II na na na na ? na na b na
PGI na na na na na na na b e
SF-12 na na na na na na na ? ?
SF-36 ? na na na þf þ na b e
BAI e Beck anxiety inventory; EQ-5D e euroqol-5D; ESS e Epworth sleepiness scale; FLP e functional limitations proﬁle; FOSQ e functional outcomes of sleep questionnaire;
HADS e hospital anxiety and depression scale; MOSAS e Maugeri obstructive sleep apnea syndrome; NHP e Nottingham health proﬁle; OSA e obstructive sleep apnea;
OSAPOSI e obstructive sleep apnea patient-oriented severity index; PGI e patient-generated index; PROM e patient-reported outcome measure; QSQ e Quebec sleep
questionnaire; SAQLIe sleep apnea quality of life index; SF-12 e short form 12; SF-36 e short form 36; SNORE25e symptoms of nocturnal obstruction and related events-25;
SOS e snore outcomes survey; SQS e sleep quality scale; SWIFT e sleepiness-wakefulness inability and fatigue test; ToDSS e time of day sleepiness scale; VAWS e visual
analogical well-being scale.
a The scores in this table were constructed as described in Table 2. “na” e not available; no studies were performed on this measurement property for this PROM.
b The measurement property “measurement error” was removed from this table because it was not assessed for any of the instruments.
c Criterion validity is not relevant for this questionnaire.
d The VAWS is a one-item PROM, meaning that internal consistency and structural validity are not relevant for this PROM.
e Due to the conﬂicting results of the factor structure of the ESS in (suspected) OSA patients, evidence on internal consistency results cannot be clearly interpreted.
f The positive score is for the mental health component of the SF-36. The physical component was only compared with unsuitable comparator instruments so its validity in
patients with OSA could not be determined.
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idence for the internal consistency of the ESS is also conﬂicting.
Moderate positive evidence for convergent validity is reported
for the BAI and the ESS (see Table S4 for pooled correlations of the
ESS). There is limited negative evidence for this property for the
hospital anxiety and depression scale (HADS), the snore outcomes
survey (SOS), and the Rotterdam sleepiness scale. The correlation of
the overall HADSwith an instrument that measures depressionwas
stronger than the correlation with the HADS depression subscale
only [60], whichwas not as expected. There is negative evidence for
convergent validity for the Rotterdam sleepiness scale and the SOS
because less than 75% of hypotheses were met.
There is a limited positive evidence base for known-groups
validity of the sleepiness-wakefulness inability and fatigue test
(SWIFT) and sleep quality scale (SQS), as patients with OSA had a
higher average score on these PROMs than normal subjects, as
expected. Known-groups validity for the ESS showed conﬂicting
evidence. Of the six studies that compared ESS scores of different
groups, four studies found expected differences [42,43,45,54], and
two studies did not [39,57].
For the BAI, discriminant validity was assessed by determining
whether the BAI could be distinguished from the depression score
of the Beck depression inventory (BDI) by performing a factor
analysis on all items of both questionnaires simultaneously. The
items of the BAI and BDI were shown to load on different factors
[52], providing limited positive evidence that they measure
different constructs.With regard to interpretability, no MIC for patients with OSA is
reported for any of the PROMs in this category. The ESS does not
show ﬂoor or ceiling effects, as can be concluded from the ranges of
scores and their graphical presentation in many of the included
studies [38,41,45,46,48,50,51,53,57]. For no other instruments there
is information on ﬂoor or ceiling effects for patients with OSA.
Scores of subgroups were presented for the BAI (male and female
patients with OSA) [52], the time of day sleepiness scale (ToDSS)
(patients with OSA before and after treatment with CPAP) [58], and
the SQS and the SWIFT (normal subjects and OSA patients) [61,63].
Scores of subgroups are also available for the ESS (normal subjects
and/or patients with different OSA severity [39,42e46,49,50,54,57],
patients with OSA before and after treatment with CPAP [44], and
for ethnicities and different genders [42]).
Generic health-related quality of life PROMs
Most measurement properties were not assessed in patients
with OSA for general health-related quality of life PROMs, which
means there is very little information available on their quality in
this patient group. Only responsiveness was assessed for ﬁve out of
six PROMs, but the evidence was either indeterminate or negative.
There is limited positive evidence for convergent validity and
known-groups validity for the mental health component of the SF-
36 (see Table S4 for pooled correlations of the SF-36). For the SF-36
and the patient-generated index (PGI) there is limited negative
evidence for responsiveness because correlations with unrelated
constructs were stronger than with related constructs. For the
I.L. Abma et al. / Sleep Medicine Reviews 28 (2016) 18e3128euroqol-5D (EQ-5D) there is limited negative evidence for
responsiveness because less than 75% of hypotheses were met.
With regard to interpretability, no information on the MIC or
ﬂoor and ceiling effects is available for the PROMs in this category.
Subgroups of patients with OSA (before and after treatment with
CPAP) were presented for the EQ-5D [67,68], the functional limi-
tations proﬁle (FLP) [67], PGI [68], and the SF-36 [67,68]. For the
short-form 12 (SF-12), scores were presented of the general pop-
ulation and OSA patients [65].
Discussion
In this review we determined the evidence base for PROMs for
health outcomes measurement in patients with OSA. We identiﬁed
22 PROMs validated in patients with OSA, categorized into three
domains: OSA-related quality of life, single OSA-related symptoms,
and generic health-related quality of life. None of the identiﬁed
PROMs has been fully validated, and many validation studies were
of insufﬁcient quality. Especially the lack of established content
validity for most of the PROMs is problematic for a patient-centered
approach to measuring health status, because the items of these
PROMs might not address the issues that patients with OSA
consider relevant or most important. Furthermore, it is important
to note that measurement error, which is particularly relevant for
the use of PROMs in clinical practice, i.e., for individual patients,
was not assessed for any of the questionnaires. Therefore the re-
sults of all PROMs should be used with caution when interpreting
scores for individual patients. Rather than relying on composite
scores of the domains, the individual questions of the PROMsmight
be more suitable for alerting a healthcare professional to the most
important problems of these patients.
The only PROMswith good content validity are four OSA-related
quality of life PROMs: the OSAPOSI, MOSAS questionnaire, QSQ and
SAQLI. Therefore, we consider these PROMs the most suitable for a
patient-centered approach of health status and we consider all four
potentially suitable for outcomemeasurement. Currently, the SAQLI
has the most evidence for good quality, but its downside is that it
contains many questions (n ¼ 56, plus 28 treatment-related
symptoms) and it is interview-administered, which makes it a
less feasible option for use in clinical practice. The QSQ (n ¼ 32) or
MOSAS questionnaire (n¼ 16, plus 7 CPAP-related questions) might
be more suitable for this purpose, as they can be ﬁlled out by the
patient and are shorter. It should be noted that the MOSAS ques-
tionnaire does not contain any questions on nocturnal symptoms, a
topic which is covered by the other three PROMs. Its CPAP-related
questions may be relevant on an individual patient level, for
those patients who get this treatment. The development article of
the OSAPOSI (n ¼ 32) reveals that this PROM contains some topics
that were not covered in other PROMs (such as occupational
impact, e.g., job loss), but the OSAPOSI is not publicly available or
retrievable via the developer. Therefore our recommendation is to
use the SAQLI for research purposes, when feasible, and either the
QSQ or MOSAS questionnaire for use in clinical practice.
The PROMs on single OSA-related symptoms all focus on
symptoms which are also addressed in the OSA-related quality of
life PROMs. None of the PROMs on OSA-related symptoms has been
well-validated or assessed for content validity. For the ESS this
oversight is speciﬁcally surprising as it had the greatest number of
validation articles devoted to it in OSA patients (n ¼ 20 studies),
and is frequently used in both research and practice to measure
sleep propensity. Similar to a recent systematic review on the ESS
[16], we conclude that the evidence regarding the quality of this
PROM is modest at best. The other PROMs in this category
measuring sleep propensity/sleepiness do not have more evidence
for their quality, but one could consider using the ToDSS or theSWIFT. The ToDSS contains the same questions as the ESS but for
three different times of day. This may be beneﬁcial for clinical
practice to identify the time of day that a patient feels most sleepy,
though in terms of outcome measurement there does not seem to
be a clear beneﬁt compared to the ESS. The SWIFT measures
sleepiness in combination with fatigue and is a possible alternative
to the ESS for measuring the main complaints related to OSA. We
would not recommend the Rotterdam sleepiness scale: it is similar
to the ESS but contains mostly yes/no questions and therefore its
scores are likely to be less sensitive. The main beneﬁt of the ESS
compared to the other sleepiness PROMs is that it is used all around
the world in both clinical practice and research, and will be familiar
to those involved with OSA.
The SQS (on subjective sleep quality) and SOS (on experienced
problems due to snoring) measure complaints that can be relevant
to OSA, but are not likely to be the main complaints. Since there is
no evidence that they are of better quality than other PROMs, we
would not recommend them for patients with OSA.
The BAI (measuring anxiety) has limited positive evidence for
several measurement properties, and based on current evidencewe
would recommend it over the use of the HADS. The HADS was the
only PROM in this review that measures depression. Since evidence
for this PROM in OSA patients is either not available or negative, a
possibility is to look outside the scope of this review for other
PROMs measuring depression.
It should also be noted that if the use of a complete disease-
speciﬁc quality of life PROM is not preferred (for example because
of a preference for a short PROM, or because only a speciﬁc
symptom needs to be measured), another option is to use one or
more domains of such a PROM, for example the “daytime sleepi-
ness” domain of the QSQ. The beneﬁt is that content validity is good
for this PROM and that some of the other measurement properties
were assessed separately for each domain, even though we did not
report our results at domain level in this review.
The main reason to use a generic health-related QoL PROM is to
be able to compare PROM scores across diseases. These PROMs will
by deﬁnition contain questions less relevant for the speciﬁc disease
studied. Therefore we would not recommend the use of generic
health-related quality of life PROMs for use in clinical practice,
especially not when acceptable disease-speciﬁc PROMs are avail-
able, as these will provide more relevant information for the dis-
ease. Of the PROMs in this review the only exception is the PGI,
which asks patients to write down and score the areas of their life
most affected by the disease, allowing for a more disease-speciﬁc
approach.
Very little evidence was found regarding the quality of generic
health-related QoL PROMs for patients with OSA. Themental health
component of the SF-36 is the only PROM with a positive score for
any of the measurement properties, and as such could be consid-
ered the best option. However, whether a generic PROM is suitable
for outcome measurement for any speciﬁc disease greatly depends
on content validity e which in this case could be described as the
degree to which the questions are relevant for this disease. The
negative evidence that we found for responsiveness for the SF-36,
EQ-5D and PGI is likely related to a lack of content validity of
these PROMs for OSA, although this has not been assessed in the
included studies. We did identify potential issues related to a lack of
content validity when devising our hypotheses, for example for the
SF-36. In this PROM, the questions about daily activities and social
functioning are assessed by asking about limitations due to
“physical health” or “emotional problems”. In our view, neither of
these categories clearly covers the main reasons for reduced func-
tioning that patients with OSA experience (i.e., sleepiness and fa-
tigue). It needs to be investigated whether problems with daily
activities or social functioning will be detected with this PROM in
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is the “vitality” domain, which is therefore most likely to be useful
in measuring outcomes for patients with OSA.
We have also noticed problems with content validity for the SF-
12 and the EQ-5D. The FLP contains items relevant for OSA patients,
but it is very long (n ¼ 136) and also contains a great many items
which are irrelevant. The Nottingham health proﬁle (NHP) part II
allows only yes/no answers to questions about how health affects
daily functioning, which is not likely to provide sensitive scores.
Furthermore, the FLP and NHP are not used often and would be of
limited use when the aim is to compare scores across diseases.
Finally, it may be hard to make a meaningful comparison of PGI
scores across diseases due to the wide range of items that can be
created by the patient.
Summarizing, the mental health component of the SF-36, and in
particular the “vitality” domain, is probably the best generic health-
related QoL PROM for OSA patients, though we remain doubtful
about its content validity and recommend the use of a disease-
speciﬁc PROM alongside it.
We did not ﬁnd many PROMs of which measurement properties
could be statistically pooled. Studies on the same PROMs and
properties were either of poor quality, or a given measurement
property was only assessed in a single study. For the measurement
properties of which we theoretically could pool data, heterogeneity
appeared too high in about half of them to allow pooling. We did
not ﬁnd a plausible explanation for this high heterogeneity.
The main strength of this review is that we used the COSMIN
checklist for a thorough evaluation of the quality of the included
studies, and complemented this with our own critical assessment
of which items on the COSMIN checklist assessed methodological
quality, and which assessed quality of reporting. This allowed us to
discriminate between studies of sufﬁcient and insufﬁcient meth-
odological quality, when deciding which studies should contribute
to the evidence base of the PROMs. Furthermore, we devised hy-
potheses for convergent validity and responsiveness where the
authors of validation articles did not, which created the opportu-
nity to use the available data to assess these measurement
properties.Practice points
This systematic review on the measurement properties of
patient-reported outcome measures (PROMs) validated in
patients with obstructive sleep apnea (OSA) shows that:
1) None of the PROMs are fully validated for patients with
OSA, and there are few high-quality validation studies.
2) For many identified PROMs there was no involvement of
patients with OSA during their development or before
the PROM was tested in patients with OSA.
3) The PROMs which did have thorough patient involve-
ment in their development are the obstructive sleep ap-
nea patient-oriented severity index (OSAPOSI), Maugeri
obstructive sleep apnea syndrome (MOSAS) question-
naire, Quebec sleep questionnaire (QSQ) and sleep ap-
nea quality of life index (SAQLI), and these are the ones
that we would recommend to use for patients with OSA.
4) The Epworth sleepiness scale (ESS) is of moderate
quality at best; a possible alternative or addition might
be the sleepiness-wakefulness inability and fatigue test
(SWIFT) even though further validation studies are
needed to confirm this.Limitations
Our study has a few limitations. First, we deviated slightly from
our original protocol [70] in which we described two comple-
mentary search strategies, while we report only one. By broadening
our original inclusion criteria for PROMs, no new PROMs were
foundwith the second search strategy.We believe that this solution
provides an article that is more easily readable, while being equally
inclusive with regard to the PROMs suitable for outcome mea-
surement in patients with OSA.
Second, the COSMIN checklist had very high demands in
assessing the validation articles, resulting in low scores for many
measurement properties. For example, the items about percentage
and handling of “missing items” of the PROMs do not seem to
follow current or historical standard practice. However, because the
scores on these items had no impact on the evidence base, we did
not change the way we handled these scores.
Third, the more subjective items on the COSMIN checklist may
cause discrepancies between reviews. A recent systematic review
[16] that assessed the measurement properties of the ESS in all
populations, assigned higher COSMIN scores than we did to more
than half of the measurement properties in the studies overlapping
with our review. However, the differences on these items did only
on a few occasions cause a different approach with regard to
contribution to the evidence base for the ESS.Fourth, we chose not to create hypotheses when the comparator
instruments (or their domains) had a construct that was too
different from the construct under study. Since some studies re-
ported over 30 correlations between unrelated constructs, this
would have resulted in many hypotheses predicting weak corre-
lations. We consider hypotheses for related constructs more valu-
able than hypotheses for unrelated constructs, and decided to base
our scores on only the former.
Finally, when discrepancies are found between hypothesized
correlations and identiﬁed correlations for convergent validity and
responsiveness, there is a possibility that the fault is not in the
validity of the PROM, but in ﬂawed hypotheses. This cannot be
avoided, but by providing all of the hypotheses that we used to
judge these measurement properties in the appendices, we do
provide transparency into our results.Conclusions
Our review found a lack of evidence for the quality of most
measurement properties of the 22 included PROMs validated in
patients with OSA. We identiﬁed four OSA-related quality of life
PROMs with thorough patient involvement in their development:
the OSAPOSI, MOSAS questionnaire, QSQ, and SAQLI. These are the
current best candidates for assessing health status in patients with
OSA. Our recommendation is to use the SAQLI for research purposes
and either the QSQ or MOSAS questionnaire for use in clinical
practice. Even though there is not enough evidence to fully judge
the quality of these PROMs, they can potentially add value to
outcome measurement or clinical practice, when they are inter-
preted with caution. Future research should focus on the further
validation of these PROMs, to estimate their suitability as outcome
measure. Of the PROMs measuring only sleepiness and fatigue, the
ESS is the most widely used PROM. However, the quality of this
PROM is moderate at best. The SWIFT could potentially serve as an
alternative or addition, if future research shows that this PROM is of
higher quality.
Research agenda
The four PROMs with thorough patient involvement in their
development (obstructive sleep apnea patient-oriented
severity index (OSAPOSI), Maugeri obstructive sleep ap-
nea syndrome (MOSAS) questionnaire, Quebec sleep
questionnaire (QSQ) and sleep apnea quality of life index
(SAQLI)) should be the focus of future high-quality valida-
tion studies. Additionally, the Epworth sleepiness scale
(ESS) and the sleepiness-wakefullness inability and fatigue
test (SWIFT), which can provide insight into the most
common complaints of OSA patients, should be validated
further.
 Structural validity and internal consistency need to be
assessed for the OSAPOSI, QSQ and SAQLI; for the
MOSAS questionnaire, previous results for these mea-
surement properties should be replicated to see if
adjustment of the proposed factor structure is necessary.
 For all four PROMs, we also recommend that their test
eretest reliability, measurement error, construct validity
(hypothesis testing) and responsiveness are (further)
assessed.
 Additional high quality validation studies are needed to
test the ESS in OSA patients, to clarify the conflicting
evidence for this widely used PROM and assess its con-
tent validity.
 The potential of the SWIFT to serve as a good PROM to
measure sleepiness and fatigue should be further
explored by assessing its content validity and other
measurement properties.
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